Developmental Research Program

发展研究计划(DRP)：项目摘要/摘要 发展研究计划(DRP)将支持遗传学和基因组学的努力 平滑肌肉瘤(LMS)：对癌症生物学认识的提高和诊断和治疗的新方法 处理孢子。这种DRP将补充或增强肉瘤翻译的多样性和深度 研究，力求确保高质量的转化性科学研究不断更新。《DRP》 支持短期研究，以建立促进假设驱动的翻译项目所需的数据。 虽然DRP将资助现有的调查人员，但一个重要的目标是确定并激发对 肉瘤研究的群体，其目前的重点可能不同，但充分和过渡相关。 此外，我们寻求吸引职业生涯早期和中期的调查人员，特别是黑人和拉丁裔或西班牙裔 调查人员。梅奥大学医学副教授史蒂文·罗宾逊将参与指导这个项目 医学院。罗宾逊博士出生于牙买加，在牙买加接受教育。在过去的4年里，他一直 得到了梅奥诊所职业发展赠款的支持，包括机构K12以及罗伯特 伍德·约翰逊基金会爱默生医学院发展计划。罗宾逊博士最近接受了 国防部创意奖。他还领导了一项ETCTN临床试验，该试验评估了 TVEC联合放射治疗局限性肉瘤。罗宾逊博士也将通过共同领导的方式参与这一孢子 我们努力改善参加临床试验的患者的多样性，并增加少数族裔教师 参与。贝克博士是这个DRP的联席主任。他是孢子首席调查员。贝克博士有 从最初发现阿霉素开始，对肉瘤的治疗做出了重要贡献 作为肉瘤患者的有效药物；新辅助治疗策略的制定 骨肉瘤和尤文肉瘤是可治愈的疾病。贝克博士有出色的领导力记录和 肉瘤转译研究领域内的合作。贝克博士最引以为豪的是他作为导师所做的努力。 现在有15位医学教授声称贝克博士是他们的导师。 罗宾逊和贝克加入了一个由经验丰富的临床医生和科学家组成的高度合格的委员会(DRP 委员会)，负责审查和评估新的试点项目，以此为基础向 孢子执行委员会(主席，朱迪·加伯)和孢子MPI，负责选择 适合资助的DRP项目。DRP委员会包括来自主要癌症中心的成员 在肉瘤科学和治疗的关键方面拥有专业知识，包括生物学和遗传学， 相关科学，肉瘤病理学，分子诊断学，肉瘤耐药性，免疫肿瘤学和 统计设计与分析。DRP将提供在这个孢子中保持创新所需的深度。

Developmental Research Program (DRP): Project Summary / Abstract The Developmental Research Program (DRP) will support the efforts of the Genetics and Genomics of Leiomyosarcoma (LMS): Improved understanding of cancer biology and new approaches to diagnosis and treatment SPORE. This DRP will complement or enhance the variety and depth of sarcoma translational research, seeking to ensure continual renewal of high-quality translational scientific investigation. The DRP supports short-range studies to establish the data needed to facilitate hypothesis-driven translational projects. Although the DRP will fund established investigators, an important goal is to identify and stimulate interest in sarcoma research among groups whose current focus may be different but sufficiently and transitionally related. In addition, we seek to attract early and mid- career investigators and especially Black and Latino or Hispanic investigators. Co-directing this program will be Steven Robinson, Associate Professor of Medicine at Mayo School of Medicine. Dr. Robinson is a Jamaican born man educated in Jamaica. For the past 4 years he has been supported by career development grants to Mayo Clinic including the institutional K12 as well as the Robert Wood Johnson Foundation Amos Medical Faculty Development Program. Dr. Robinson is recent recipient of Department of Defense IDEA Award. He also leads a ETCTN clinical trial that evaluates the combination of TVEC with radiation therapy for localized sarcoma. Dr. Robinson will also participate in this SPORE by co-leading our efforts to improve diversity in patients enrolled in clinical trials as well as increasing minority faculty participation. Dr. Baker is the Co-Director of this DRP. He is the SPORE Principal Investigator. Dr. Baker has made important contributions to the treatment of sarcomas beginning with the initial identification of doxorubicin as an effective drug in sarcoma patients; the establishment of neo-adjuvant therapy strategy making osteosarcoma and Ewing sarcoma curable diseases. Dr. Baker has an outstanding record of leadership and collaboration within the sarcoma translational research field. Dr. Baker is most proud of his mentorship efforts. Now 15 Professors of Medicine claim Dr Baker as their mentor. Robinson and Baker are joined by a highly qualified committee of experienced clinician-scientists (DRP Committee) which reviews and evaluates new pilot projects as the basis of providing recommendations to the SPORE Executive Committee (Chair, Judy Garber) and the SPORE MPI, who bear the responsibility to select DRP projects appropriate for funding. The DRP Committee includes members from major cancer centers who possess expertise in key aspects of sarcoma science and therapeutics, including biology and genetics, correlative science, sarcoma pathology, molecular diagnostics, sarcoma drug resistance, immuno-oncology and statistical design and analysis. The DRP will provide the depth required to maintain innovation in this SPORE.